Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 1, 2008, Pages 206-209

  Llibre, Josep M ^a   Domingo, Pere ^b   Del Pozo, Miguel A ^c   Miralles, Celia ^d   Galindo, Maria J ^e   Viciana, Isabel ^f   Moreno, Santiago ^g   Schapiro, Jonathan M ^h   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL SANT PAU   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^d HOSPITAL XERAL CALDE   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h SHEBA MEDICAL CENTER   (Israel)

Author keywords

Antiretroviral treatment; Expert opinion; Genotypic resistance testing; Salvage therapy; Teleconference

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; E-MAIL; FEMALE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; PATIENT COUNSELING; SALVAGE THERAPY; SUPERINFECTION; TREATMENT REFUSAL; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; REMOTE CONSULTATION; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 37549012189     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm438     Document Type: Article

References (18)

1. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-43.
2. Panel on Clinical Practices for Treatment in HIV Infection convened by Department of Health and Human Services (DHHS). Guidelines For The Use Of Antiretroviral Agents in HIV-Infected Adults and Adolescents, 10 October 2006. http://aidsinfo.nih.gov (31 August 2007, date last accessed).
3. Palella FJ, Armon C, Chmiell JS et al. Enhanced survival associated with use of HIV susceptibility testing among HAART-experienced patients in the HIV Outpatient Study (HOPS). In: Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2006. Abstract 654. Foundation for Retrovirology and Human Health, VA, USA.
4. Zolopa AR, Lazzeroni LC, Rinehart A et al. Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: An international comparison (The Guess Study). Clin Infect Dis 2005; 41: 92-9.
5. Tural C, Ruiz L, Holtzer C et al. Clinical utility of HIV-1 genotyping and expert advice: The Havana trial. AIDS 2002; 16 209-18.
6. Baxter JD, Mayers DL, Wentworth DN et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14 F83-93.
7. Bossi P, Peytavin G, Ait-Mohand H et al. GENOPHAR: A randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 2004; 5: 352-9.
8. Badri SM, Adeyemi OM, Max BE et al. How does expert advice impact genotypic resistance testing in clinical practice? Clin Infect Dis 2003; 37: 708-13.
9. Expert Panel of GESIDA and the Spanish AIDS Plan. Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infections (Update January 2007). Enferm Infecc Microbiol Clin 2007; 25: 32-53.
10. Torti C, Quiros-Roldan E, Regazzi M et al.A randomized controlled trial to evaluate antiretroviral therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: The resistance and dosage adapted regimens (RADAR) study. Clin Infect Dis 2005; 40: 1828-36.
11. DeAngelis CD, Berwick DM. Author in the room: A teleconference series to accelerate health care improvement. JAMA 2005; 293: 1004.
12. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med 2006; 14 125-30.
13. Deeks SG, Hoh R, Neilands TB et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 192: 1537-44.
14. Ruiz L, Paredes R, Gomez G et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007; 21: 169-78.
15. Hicks CB, Cahn P, Cooper DA et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006; 368: 466-75.
16. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-95.
17. Castagna A, Danise A, Menzo S et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: A randomized pilot study (E-184V study). AIDS 2006; 20: 795-803.
18. Napravnik S, Keys JR, Quinlivan EB et al. Triple-class antiretroviral drug resistance: Risk and predictors among HIV-1-infected patients. AIDS 2007; 21: 825-34.